USE OF CONCENTRATED SOLUTION OF LECITHIN IN KAHN ANTIGEN*†

BY
ELIZABETH B. McDERMOTT, FRANK T. NAKAMURA, MARY R. DOCKRILL, AND REUBEN L. KAHN

Serology Laboratory, University Hospital, and Department of Dermatology and Syphilology, University of Michigan Medical School, Ann Arbor, Michigan

In the standardization of Kahn antigen, a lipid extract is occasionally encountered which, on being mixed with salt solution, results in an antigen suspension containing non-dispersible lipid aggregates. Such a suspension obviously cannot be used in a flocculation test for syphilis, because, when it is mixed with non-syphilitic serum, instead of the result being total freedom from particles in the serum-suspension mixture, the presence of these non-dispersible aggregates is bound to be confused with floccules of a syphilitic reaction.

Indications are that the non-dispersibility of these aggregates in the antigen-salt solution suspension is due to a disproportionate amount of lecithin to cardiolipin or a cardiolipin-like substance contained in the lipid extract. The term “cardiolipin”, being a familiar one, will be used in this article instead of “cardiolipin-like substance”. Briefly, it is assumed that Kahn antigen contains lecithin, cardiolipin, cholesterol, and additional lipids of undetermined nature. When the antigen is mixed with salt solution, the cardiolipin in the antigen tends to render the antigen suspension aggregates non-dispersible, while the lecithin in the antigen tends to disperse them. When cardiolipin and lecithin are in proper equilibrium, a desirable antigen results, and the aggregates are in an optimum state for dispersion in additional salt solution or in serum. When one or the other lipids is in excess, the antigen requires appropriate correction.

That cardiolipin and lecithin play a major role in Kahn antigen can be judged from the fact that this antigen and cardiolipin-lecithin-cholesterol antigen behave with close similarity in the Kahn technique (Kahn, 1950). The formula for cardiolipin-lecithin-cholesterol antigen, as used in the Kahn technique in this laboratory side by side with Kahn antigen, consists of approximately 1 per cent. lecithin, 0.1 per cent. cardiolipin, and 0.025 per cent. cholesterol in absolute alcohol. In the preparation of the antigen suspensions with Kahn and with cardiolipin-lecithin-cholesterol antigens, the same technique is employed for mixing the antigen with the salt solution. The resulting antigen suspensions have essentially the same physical appearance and show the same behaviour with salt solution and serum. The titre of cardiolipin-lecithin-cholesterol antigen is obtained by following the same technique as for the titre of Kahn antigen. When the two antigens are employed side by side in the three serum: antigen suspension ratios in the Kahn test, the resulting serologic pattern is also essentially the same. For example, a serum showing a reading of, say, — 24 with Kahn antigen, is likely to show the same reading with the cardiolipin-lecithin-cholesterol antigen.

Quantitative chemical determinations of cardiolipin and lecithin in Kahn antigen, in relation to the other lipids present, are under study in this laboratory. Thus far, Kahn antigen has yielded lecithin and a cardiolipin-like substance qualitatively, by purification of barium and cadmium precipitates, according to Pangborn’s methods (Pangborn, 1945, 1951).

The role of the additional lipids in Kahn antigen, apart from the cardiolipin, lecithin, and cholesterol, is believed to be somewhat similar to that of “protective” colloids to the cardiolipin and lecithin. This view is suggested by the fact that the Kahn test with cardiolipin-lecithin-cholesterol antigen is far more readily affected by slight variations in technique than the same test with Kahn antigen. The test with Kahn antigen seems technically hardly compared with the test with cardiolipin-lecithin-cholesterol antigen.

It is possible also that the additional lipids in Kahn antigen play an important role in the universal

* Received for publication June 3, 1957.
† This study was aided by a grant from the Difco Laboratories, Inc., Detroit, Mich., U.S.A.
serologic reaction (Kahn, 1951). Cardiolipin-lecithin-cholesterol antigen, when used according to
the formula employed in the Kahn technique, is not as applicable to the technique of the universal
reaction as is Kahn antigen. It may be, however, that a modified formula would make cardiolipin-
lecithin-cholesterol antigen fully applicable to the universal reaction.

In this article we are concerned particularly with
attempts to standardize such Kahn antigens as are
occasionally encountered which, when mixed with
salt solution, result in antigen suspensions contain-
ing non-dispersible aggregates, and which cannot
therefore be used with serum. First, the several
steps in the standardization of Kahn antigen will be
briefly reviewed. Then, the results of an experiment
will be presented showing that the addition of
cardiolipin to Kahn antigen changes the antigen-salt
solution suspension of dispersible aggregates to a
suspension of non-dispersible aggregates; and the
subsequent addition of lecithin to the antigen leads
to an antigen suspension in which the aggregates
have again become dispersible. Finally, data will be
presented of the correction of antigens, which give
suspensions with salt solution of non-dispersible
aggregates, to the requirements of standard Kahn
antigen by the addition of small amounts of a
concentrated lecithin solution.

Standardization of Kahn Antigen

The conversion of a newly prepared lipid extract
into standard Kahn antigen requires three basic
steps:

(1) The determination of the antigen titre with
0.9 per cent. NaCl solution is accomplished
by means of a titration in which each of
several amounts of salt solution is appropri-
ately mixed with 1 ml. antigen. The titre
indicates the correct quantity of salt solution
to be mixed with the antigen, under standard
conditions, for the production of an antigen
suspension fit for trial use with serum. The
correct type of suspension contains lipid
aggregates of such physical nature that they
disperse spontaneously when added to serum
or to salt solution.

(2) When the antigen suspension at the antigen
titre is mixed with syphilitic serum, the
dispersion of the lipid suspension aggregates
is followed by the rapid formation of new
lipid-globulin floccules. These floccules
should have the same qualitative and
quantitative characteristics as those obtained
with standard Kahn antigen.

(3) When the antigen suspension is mixed with
non-syphilitic serum, no lipid-globulin
floccules are formed. In addition, the
resulting mixture must have a degree of
opalescence which conforms to standard re-
quirements. The opalescence must be free
from turbidity on the one hand and from
over-clarity on the other.

A newly-prepared lipid extract may not conform
to the first standardization requirement by not giving
an antigen titre. Thus, no matter in what proportion
this extract is mixed with salt solution throughout
the titre range, the resulting lipid aggregates are not
dispersible in serum. That extract is therefore not fit
for trial use with serum, since all sera, whether
syphilitic or non-syphilitic, will show the presence
of these aggregates. Alternatively, if the extract does
give a titre with salt solution, trial tests with serum
might show that both the sensitivity with syphilitic
serum and the degree of opalescence with non-
syphilitic serum are out of range compared with
standard Kahn antigen.

The use of 5 per cent. solutions of commercial
lecithin in the correction of over-sensitive antigens
was previously reported from this laboratory
(Wheeler, Brandon, and Kahn, 1947). Because of the
weak solution of this type of lecithin, relatively large
amounts had to be added to an antigen for correction
and this fact greatly limited its use. Experience with
the use of solutions of purified lecithin of about
50 per cent. concentration in the standardization of
Kahn antigen showed that lipid extracts, which were
outside the standardization range because of non-
dispersible aggregates in the antigen suspension and
which ordinarily would have had to be discarded,
became convertible into standard antigen. Many of
these extracts gave no titre and therefore could not
be tested with serum. Others that did give a titre
showed a degree of sensitivity with syphilitic serum,
or of opalescence with non-syphilitic serum, not in
conformity with standard antigen. In the subse-
quent pages, several instances will be presented of
such extracts which were corrected to standard
requirements.

Effect of Adding Cardiolipin* and Lecithin*
to Kahn Antigen

Preliminary experiments indicated that cardio-
lipin added to Kahn antigen tends toward non-
dispersion of the lipid aggregates in the antigen
suspension, while lecithin added to the antigen tends
toward their dispersion. These opposing tendencies

* Cardiolipin and concentrated lecithin solutions employed in this
experiment were kindly furnished by the Difco Laboratories Inc.,
Detroit.
of cardiolipin and lecithin are illustrated in the following experiment.

To 100 ml. standard Kahn antigen (Lot 214 in current use) were added 50 ml. 0·6 per cent. cholesterolized alcohol, the percentage of cholesterol being the same as in the Kahn antigen. The dilution of the antigen was desired in order to reduce the amounts of cardiolipin and lecithin to be used in the experiment.

The diluted antigen, which obviously no longer conformed to the requirements of standard Kahn antigen, was then divided into 7 fractions of 10 ml. each.

Fraction 1 was titrated in the usual manner with salt solution. The titration range was 1 ml. antigen + 1·1 ml. salt solution; 1 ml. antigen + 1·2 ml. salt solution; 1 + 1·3; 1 + 1·4; and 1 ml. antigen + 1·5 ml. salt solution. All five titration mixtures (Fraction 1) contained lipid aggregates which were readily dispersed on the addition of salt solution, leading to very nearly water-clear solutions, because of the high dilution of the antigen with the cholesterolized alcohol.

To Fraction 2 was added 0·1 per cent. (10 mg.) cardiolipin and the modified antigen was titrated with salt solution. The antigen plus salt solution mixtures of 1 + 1·1 and 1 + 1·2 now showed aggregates which were only partially dispersed on adding salt solution. The remaining antigen plus salt solution mixtures showed aggregates which were completely dispersed and which were apparently not affected by the small amount of cardiolipin added to the antigen.

When 0·5 per cent. (50 mg.) cardiolipin was added to Fraction 3, four of the titration mixtures (1 + 1·1, 1 + 1·2, 1 + 1·3, and 1 + 1·4) showed aggregates which were non-dispersible, and the last mixture (1 + 1·5) showed aggregates partially dispersible. When, however, not only 0·5 per cent. cardiolipin but also 0·5 per cent. of a lecithin solution of high (28 per cent.) concentration, were added to Fraction 4, the titration picture began to show a change from non-dispersibility toward dispersibility of the aggregates.

As is evident from the results given by Fractions 5 and 6 in Table I, 2 per cent. of the concentrated lecithin solution was required to overcome the non-dispersible tendency of the lipid aggregates brought about by the 0·5 per cent. cardiolipin. Antigen Fraction 7 was used as a control.

In the present article, that property of lecithin which changes non-dispersible to dispersible suspensions is stressed because it offers a means for the standardization of antigens which, on preparation, show non-dispersible aggregates in the suspensions and, as indicated, would be unfit for use.

Use of Concentrated Lecithin in Standardization of Kahn Antigen

The lecithin solutions were prepared from egg yolk according to Pangborn's procedure (Pangborn, 1951), with the exception that, after the last step in the purification, the ether-acetone solution of the lecithin was dried in vacuo. A concentrated solution was then prepared by the addition of 2 ml. absolute ethyl alcohol per g. lecithin. To each lecithin solution was then added 0·6 per cent. ash-free cholesterol. It should be mentioned that the concentrated lecithin solutions were of a yellowish colour, although in high dilution this colour is not noted.

The following Tables were taken from the antigen standardization records of this laboratory. Table II gives the titration picture of antigen Lot 462, without the addition of lecithin solution (Titration 1), and after the addition of lecithin solution in the amounts of 0·3 per cent. (Titration 2), 0·5 per cent. (Titration 3), and 0·6 per cent. (Titration 4), to test-samples of the antigen.

It is evident from the Table that, without the addition of lecithin, the antigen gives no titre. The

<table>
<thead>
<tr>
<th>Table I</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEGREE OF CLARITY OF ANTIGEN SUSPENSION IN SALT SOLUTION AND DISPERSIBILITY OF AGGREGATES (TITRATION EFFECT OF ADDITION OF CARDIOLIPIN TO KAHN ANTIGEN FOLLOWED BY LECITHIN, LEADING TO NON-DISPERSIBLE AGGREGATES IN ANTIGEN SUSPENSION, FOLLOWED BY THEIR DISPERSION)</td>
</tr>
<tr>
<td>Antigen Fraction</td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>Cardiolipin Added (per cent.)</td>
</tr>
<tr>
<td>Lecithin Added (per cent.)</td>
</tr>
<tr>
<td>Antigen Suspensions: 1 ml. Antigen plus Salt Solution (ml)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

Figures in this Table and in Tables II, IV, VI indicate degree of clarity of suspension in salt solution:

94 = water-clear. 95 = very nearly water-clear. 100 = desirable opalescence, titre.

96 = nearly water-clear. 101 = opalescent. 97 = too cloudy. 102 = cloudy.

98 = slightly too clear. 103 = heavily turbid.

Signs in brackets indicate degree of dispersion of aggregates in salt solution:

(−) = aggregates dispersed. (±) = aggregates partially dispersed. (+) = aggregates not dispersed.
antigen suspensions in the entire titration range (consisting of 1 ml. antigen + 1:1 ml. salt solution; 1 ml. + 1:2; 1 ml. + 1:3; 1 ml. + 1:4; 1 ml. + 1:5; and 1 ml. + 1:7) contain lipid aggregates that are non-dispersible in salt solution. This means that the aggregates will also not be dispersible in serum. The antigen therefore is not fit for trial use with serum, since the aggregates will be suspended in all sera with which the suspensions are mixed.

When 0-3 per cent. lecithin was added to a test-sample of the antigen, partial dispersibility of the aggregates began to be noted, as indicated under Titration 2 in the Table. The antigen was still not fit for trial use, but 0-5 per cent. lecithin added to the antigen led to a typical titration picture. The titre was 1 ml. antigen + 1:2 ml. salt solution. At this titre, the lipid aggregates in the resulting suspension were completely dispersed, and the opalescence conformed to the requirements of standard Kahn antigen. The same titre was obtained on the addition of 0-6 per cent. lecithin to the extract, but it did not seem desirable to use that amount when 0-5 per cent. was sufficient to provide a titre.

An interesting aspect of the addition of lecithin to antigen is that a “flat” titration picture is changed to a “sloping” titration. This change is illustrated in the Figure. The antigen extract without the addition of lecithin, or with the addition of 0-3 per cent. lecithin, gives essentially a “flat” titration picture, in that each of the seven lipid suspensions in the titration are within one zone, in this instance, in the zone of turbidity.

However, when either 0-5 or 0-6 per cent. lecithin is added to the extract, a “sloping” titration picture is obtained, the curve extending from the zone of turbidity, through the zone of desirable opalescence, into the zone of clarity. Experience with Kahn antigens extending through more than 30 years indicates that antigens giving “sloping” titrations retain their keeping qualities better than those giving “flat” titrations.

Having established a titre for Lot 462, the next step was to determine the sensitivity of the antigen with syphilitic serum, using Kahn standard antigen as a control. Table III gives the comparative results

For explanation of numbers 95-103 and symbols, see footnote to Table I.

* Titre is 1 ml. antigen + 1:2 ml. salt solution.

---

**Table II**

<table>
<thead>
<tr>
<th>Amount of Concentrated Lecithin Added to Antigen (per cent.)</th>
<th>None</th>
<th>0:3</th>
<th>0:5</th>
<th>0:6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Titrations</td>
<td>1:1</td>
<td>103 (+)</td>
<td>103 (+)</td>
<td>101 (−)</td>
</tr>
<tr>
<td>Antigen Suspensions: 1 ml. Antigen plus Salt Solution (ml.)</td>
<td>1:2</td>
<td>103 (+)</td>
<td>103 (+)</td>
<td>100 (−)*</td>
</tr>
<tr>
<td></td>
<td>1:3</td>
<td>103 (+)</td>
<td>103 (+)</td>
<td>99 (−)</td>
</tr>
<tr>
<td></td>
<td>1:4</td>
<td>103 (+)</td>
<td>102 (±)</td>
<td>98 (−)</td>
</tr>
<tr>
<td></td>
<td>1:5</td>
<td>103 (+)</td>
<td>102 (±)</td>
<td>98 (−)</td>
</tr>
<tr>
<td></td>
<td>1:7</td>
<td>102 (±)</td>
<td>102 (±)</td>
<td>98 (−)</td>
</tr>
</tbody>
</table>

---

**Figure**—Change from a “flat” (undesirable) to a “sloping” (desirable) titration of Kahn antigen by addition of concentrated lecithin, in adjustment of Antigen Lot 462.

---

**Table III**

<table>
<thead>
<tr>
<th>Serum No.</th>
<th>Sensitivity of Lot 462 same as Standard Antigen</th>
<th>Sensitivity of Lot 462 lower than Standard Antigen</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Antigen Lot 462, 0:5 per cent. Lecithin Added</td>
<td>Antigen Lot 462, 0:6 per cent. Lecithin Added</td>
</tr>
<tr>
<td></td>
<td>Titre 1:1-2</td>
<td>Titre 1:1-3</td>
</tr>
<tr>
<td>1</td>
<td>— — — *</td>
<td>— — —</td>
</tr>
<tr>
<td>2</td>
<td>3 4 4</td>
<td>3 4 4</td>
</tr>
<tr>
<td>3</td>
<td>— 4 4</td>
<td>— 4 4</td>
</tr>
<tr>
<td>4</td>
<td>— 3 4</td>
<td>— 4 4</td>
</tr>
<tr>
<td>5</td>
<td>— 2 4</td>
<td>— 2 4</td>
</tr>
<tr>
<td>6</td>
<td>1 4 1</td>
<td>1 4 1</td>
</tr>
<tr>
<td>7</td>
<td>— 1 4</td>
<td>— 1 4</td>
</tr>
<tr>
<td>8</td>
<td>— 2 3</td>
<td>— 3 3</td>
</tr>
<tr>
<td>9</td>
<td>— 1 4</td>
<td>— 1 4</td>
</tr>
<tr>
<td>10</td>
<td>— — 1</td>
<td>— — 1</td>
</tr>
</tbody>
</table>

* Opalescence conforms to that of standard antigen.

---

**CONCENTRATED LECITHIN IN KAHN ANTIGEN**
BRITISH JOURNAL OF VENEREAL DISEASES

obtained with eight weakly-positive syphilitic sera and two non-syphilitic sera.

It is evident that the antigen extract to which was added 0.5 per cent. lecithin gave results almost identical to those given by standard Kahn antigen, while the extract to which was added 0.6 per cent. lecithin gave results weaker than those given by standard antigen. Additional comparative studies with fifty syphilitic and non-syphilitic sera are not listed in these Tables because the results are of the same character as those given in Table III. Emphasis should be given to the fact that the tests with non-syphilitic sera showed a degree of opalescence that conformed to standard requirements when employing the antigen corrected with 0.5 per cent. concentrated lecithin solution.

Occasionally, in titrating a newly-prepared antigen with salt solution, a “titration zone” will be noted. Such a zone is illustrated under Titration I in Table IV. In that titration, a suspension prepared by mixing 1 ml. antigen with 1.4 ml. salt solution, contains dispersible lipid aggregates, and on the surface it might seem suitable as a titre for trial use with serum. However, when 1 ml. antigen is mixed either with 0.1 ml. more or 0.1 ml. less of salt solution (actually, with 1.3 or 1.5 ml. salt solution) the resulting suspensions contain non-dispersible aggregates and are not suitable for trial use. Therefore, the use of 1.4 ml. salt solution would result in a suspension having too narrow a zone for a titre.

TABLE IV
EFFECT OF ADDING CONCENTRATED LECITHIN TO KAHN ANTIGEN SHOWN BY RESULTS OBTAINED IN THREE TITRATIONS, ILLUSTRATED WITH ANTIGEN SUSPENSIONS (ANTIGEN LOT 190) OF INCREASED AMOUNTS OF SALT SOLUTION, AND SHOWING THAT THE ADDITION OF LECITHIN MAY OVERCOME A “TITRATION ZONE”

<table>
<thead>
<tr>
<th>Amount of Concentrated Lecithin Added to Antigen (per cent.)</th>
<th>None</th>
<th>0-3</th>
<th>0-3 and 12 per cent. of Cholesterolized Alcohol Added</th>
</tr>
</thead>
<tbody>
<tr>
<td>Titration</td>
<td></td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Antigen Suspensions</td>
<td></td>
<td>1-1</td>
<td>103 (+)</td>
</tr>
<tr>
<td>1 ml. Antigen plus Salt Solution (ml)</td>
<td>1-2</td>
<td>103 (+)</td>
<td>99? (±)*</td>
</tr>
<tr>
<td></td>
<td>1-3</td>
<td>103 (+)</td>
<td>98 (±)</td>
</tr>
<tr>
<td></td>
<td>1-4</td>
<td>103 (±)</td>
<td>97 (±)</td>
</tr>
<tr>
<td></td>
<td>1-5</td>
<td>102 (±)</td>
<td>96 (±)</td>
</tr>
<tr>
<td></td>
<td>1-7</td>
<td>103 (±)</td>
<td>95 (±)</td>
</tr>
</tbody>
</table>

For explanation of numbers ranging from 95 to 103 and symbols, see footnote to Table I.
* Titre is 1 ml. antigen + 1.15 ml. salt solution.

On the addition of 0.3 per cent. of lecithin to such an antigen, a “sloping” titration picture is obtained, with a titre of 1 ml. antigen + 1.15 ml. salt solution. Yet, the obtaining of a titre did not prove to be the answer to this antigen standardization problem as was shown by the fact that, when tested with syphilitic sera, the antigen proved to be undersensitive compared with standard Kahn antigen (Table V).

TABLE V
ADJUSTMENT OF KAHN ANTIGEN SENSITIVITY WITH CONCENTRATED LECITHIN TO BRING AN ANTIGEN TO STANDARD REQUIREMENTS

<table>
<thead>
<tr>
<th>Sensitivity of Lot 190 Antigen</th>
<th>Sensitivity of Lot 190 Antigen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Same as Standard Antigen</td>
<td>Lower than Standard Antigen</td>
</tr>
<tr>
<td>Antigen Lot 190, Kahn Standard Antigen Lot 185</td>
<td>Antigen Lot 190, Kahn Standard Antigen Lot 185</td>
</tr>
<tr>
<td>Serum No.</td>
<td>Titre</td>
</tr>
<tr>
<td>10</td>
<td>1+1-15</td>
</tr>
<tr>
<td>2</td>
<td>4 4 4</td>
</tr>
<tr>
<td>3</td>
<td>4 4 4</td>
</tr>
<tr>
<td>4</td>
<td>4 4 4</td>
</tr>
<tr>
<td>5</td>
<td>4 4 4</td>
</tr>
<tr>
<td>6</td>
<td>4 4 4</td>
</tr>
<tr>
<td>7</td>
<td>4 4 4</td>
</tr>
<tr>
<td>8</td>
<td>4 4 4</td>
</tr>
<tr>
<td>9</td>
<td>4 4 4</td>
</tr>
<tr>
<td>10</td>
<td>4 4 4</td>
</tr>
</tbody>
</table>

* Opalescence conforms to that of standard antigen.

It may be that 0.3 per cent. lecithin proved to be a greater amount than was necessary to add to the antigen for correct sensitivity, but because of the correctly sloping titration, it did not seem desirable to change this amount of lecithin. Accordingly, another step was used to increase the sensitivity of the antigen, viz., dilution of the antigen with ethyl alcohol containing 0.6 per cent. cholesterol, to conform to the amount of this lipid contained in the antigen. That step consisted of diluting two test samples of the antigen, 6 and 12 per cent. respectively, with cholesterolized alcohol. It was found that the 12 per cent. diluted sample brought the sensitivity of the antigen to standard requirements. Evidently this dilution did not overcome the lecithin effect on the antigen.

Tables VI and VII give yet another illustration of an antigen, originally not fit for use because it gave no titre, which was converted into standard Kahn antigen by the addition of the optimum amount of concentrated lecithin (in this case 0.5 per cent.).

Correction of Antigens that almost meet Standard Requirements

A newly-prepared lipid extract may, to a small degree, prove to be either more or less sensitive than standard Kahn antigen. Such an extract can often
**CONCENTRATED LECITHIN IN KAHN ANTIGEN**

**TABLE VI**

EFFECT OF ADDING CONCENTRATED LECITHIN TO KAHN ANTIGEN SHOWN BY RESULTS OBTAINED IN FIVE TITRATIONS, ILLUSTRATED WITH ANTIGEN SUSPENSIONS (ANTIGEN LOT 466) OF INCREASED AMOUNTS OF SALT SOLUTION

<table>
<thead>
<tr>
<th>Amount of Concentrated Lecithin Added to Antigen (per cent.)</th>
<th>None</th>
<th>0.2</th>
<th>0.3</th>
<th>0.5</th>
<th>0.6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Titrations</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>1-1</td>
<td>103 (+)</td>
<td>103 (+)</td>
<td>103 (+)</td>
<td>101 (+)</td>
<td>101 (−)</td>
</tr>
<tr>
<td>1-2</td>
<td>103 (+)</td>
<td>103 (+)</td>
<td>103 (±)</td>
<td>101 (−)*</td>
<td>100 (−)*</td>
</tr>
<tr>
<td>1-3</td>
<td>103 (+)</td>
<td>102 (±)</td>
<td>103 (±)</td>
<td>100 (−)</td>
<td>99 (−)</td>
</tr>
<tr>
<td>1-4</td>
<td>103 (+)</td>
<td>102 (±)</td>
<td>102 (±)</td>
<td>98 (−)</td>
<td>98 (−)</td>
</tr>
<tr>
<td>1-5</td>
<td>103 (+)</td>
<td>102 (±)</td>
<td>102 (±)</td>
<td>98 (−)</td>
<td>97 (−)</td>
</tr>
<tr>
<td>1-7</td>
<td>102 (+)</td>
<td>103 (+)</td>
<td>102 (±)</td>
<td>98 (−)</td>
<td>96 (−)</td>
</tr>
</tbody>
</table>

For explanation of numbers ranging from 96 to 103 and symbols, see footnote Table I.

* Titre is 1 ml. antigen + 1·2 ml. salt solution.

**TABLE VII**

ADJUSTMENT OF KAHN ANTIGEN SENSITIVITY WITH CONCENTRATED LECITHIN TO BRING AN ANTIGEN TO STANDARD REQUIREMENTS

<table>
<thead>
<tr>
<th>Serum No.</th>
<th>Antigen Lot 466, 0·5 per cent. Lecithin Added</th>
<th>Kahn Standard Antigen Lot 203</th>
<th>Serum No.</th>
<th>Antigen Lot 466, 0·6 per cent. Lecithin Added</th>
<th>Kahn Standard Antigen Lot 203</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Titre 1+1·2</td>
<td>Titre 1+1·3</td>
<td>Titre 1+1·1</td>
<td>Titre 1+1·3</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>−     −</td>
<td>−</td>
<td>−</td>
<td>−</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>+     4</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>+     4</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>+     4</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>+     4</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>+     4</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>+     4</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>+     4</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>+     4</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>+     4</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td></td>
</tr>
</tbody>
</table>

* Opalescence conforms to that of standard antigen.

For a high sensitivity of an antigen, or a very low sensitivity, it may be necessary to increase the titre by adding a small amount of lecithin. In such cases, an increase of titre to 1+1·3 is sometimes necessary to bring the antigen to the standard requirements. Reduced sensitivity, which is due to dilution, and increased sensitivity, which is due to the addition of lecithin, are both expressed in terms of the changes in titre of the antigen. It is important to note that these changes in titre do not affect the sensitivity of the antigen.

If a change in the titre of the antigen does not produce the desired results, dilution of the antigen with cholesterolized alcohol is undertaken. Of interest is the fact that a 10 or 20 per cent. dilution may increase the sensitivity of an under-sensitive antigen, or decrease the sensitivity of an over-sensitive antigen, to standard requirements.

This unusual effect of dilution may stem from the reason for the low or too high sensitivity of the antigen. Thus, if an antigen is under-sensitive primarily because of a relative excess of lecithin in relation to cardiolipin, the reduction of the lecithin by dilution should increase the sensitivity of the antigen. It is true that such dilution also reduces the amount of cardiolipin, which in turn would tend to lower the sensitivity, but apparently the dominant effect of dilution on this type of antigen is the increase in sensitivity resulting from the reduction in the amount of lecithin. However, if the antigen is low in sensitivity primarily because of an insufficient amount of cardiolipin, then any dilution of the antigen with cholesterolized alcohol would only further reduce the sensitivity by reducing the amount of this lipid.

Let us now consider an antigen too high in sensitivity, in which dilution with cholesterolized alcohol reduces the sensitivity. Most likely such an antigen is too rich in cardiolipin, and dilution reduces the amount of this lipid. It is recognized that dilution also tends to reduce the amount of lecithin in the antigen, which should lead to an increase in sensitivity. If, however, the dominant factor in the high sensitivity of the antigen is the high concentration of cardiolipin, the effect of diluting this lipid may be far greater than the effect of diluting the lecithin.

Years ago, in this laboratory, over-sensitive antigens were reduced in sensitivity by increasing the concentration of the lipids of the non-cholesterolized extracts. The technique was to evaporate a given fraction of an extract and dissolve the residue in the cholesterolized extract. In such an instance, the reduction in the sensitivity may have

---

antigen, or decrease the sensitivity of an over-sensitive antigen, to standard requirements.
been largely due to the increase in the amount of lecithin in the antigen obtained from the evaporated residue. This increased amount of lecithin in the antigen must have masked the accompanying increase in the amount of cardiolipin contained in the evaporated residue.

Another aspect of antigen preparation may be mentioned. Powdered heart muscle that produces Kahn antigen of under-sensitivity may be modified by a simple technique to produce an antigen close to standard requirements. All that is necessary is to extract the powder with ether, according to the usual technique, and then to expose it to air by spreading it out in a thin layer at room temperature. Such exposure may be for from 24 to 72 hours, as determined by trial, after which the extraction with alcohol is carried out. It is possible that this exposure breaks down some of the lecithin or its precursors without affecting the more stable cardiolipin, thus leading to the increase in sensitivity of the extract. Occasionally also, powdered heart muscle, which produces an under-sensitive antigen, has to be aged for a month or more so that it may yield an extract close in sensitivity to standard requirements. It may be that here also we are dealing with a situation in which some lecithin is broken down because of the aging of the powder.

Summary

Certain lipid extracts, prepared according to the Kahn antigen technique, when mixed with salt solution, result in antigen suspensions containing heavy non-dispersible lipid aggregates throughout the antigen titration range. Such extracts, which it had not been possible to correct to Kahn standard antigen because of the persistence of these aggregates, were found to be readily corrected by the addition of a small amount of a concentrated solution of lecithin. The lecithin so modified the extract as to produce, with salt solution, antigen suspensions with the following characteristics:

1. They contain dispersible aggregates.
2. They permit a correct antigen titre to be obtained.
3. They give positive flocculation results of standard sensitivity.
4. They give negative flocculation results of correct opalescence.

It is believed that the non-dispersible lipid aggregates in antigen suspensions are due to the presence of an excess of cardiolipin or a cardiolipin-like substance in relation to lecithin in the lipid extract. When a known solution of cardiolipin was added to Kahn antigen, dispersible aggregates in the antigen suspensions were changed to non-dispersible aggregates, and these, in turn, were rendered dispersible by the addition to the antigen of a small amount of a concentrated solution of lecithin.

REFERENCES


———(1951). Ibid., 188, 471.

Use of Concentrated Solution of Lecithin in Kahn Antigen

Elizabeth B. McDermott, Frank T. Nakamura, Mary R. Dockrill and Reuben L. Kahn

*Br J Vener Dis* 1957 33: 182-188
doi: 10.1136/sti.33.3.182

Updated information and services can be found at: [http://sti.bmj.com/content/33/3/182.citation](http://sti.bmj.com/content/33/3/182.citation)

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to: [http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to: [http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to: [http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)